ALNY:US
$322.83
1.439%
Alnylam Pharmaceuticals Inc.News & Events
Last updated: Jun 27, 2025, 7:35 PM ET
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
Business Wire JUN 18, 2025 10:05 AM EDT− R&D Organization Positioned to Deliver Next Wave of Transformative RNAi Therapeutics...READ ARTICLEInstil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
GlobeNewswire JUN 11, 2025 7:00 AM EDTDALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL)...READ ARTICLEAlnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Business Wire JUN 9, 2025 6:00 AM EDT− First and Only RNAi Therapeutic Approved by the European Commission for the Treatment of...READ ARTICLEAlnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
Business Wire MAY 28, 2025 8:00 AM EDTAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced ...READ ARTICLEAlnylam Issues 2024 Corporate Responsibility Report
Business Wire MAY 20, 2025 9:00 AM EDT– Contains New Disclosures of Company’s Impact on the Environment – Includin...READ ARTICLEAMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
Business Wire MAY 17, 2025 5:50 AM EDT– Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlig...READ ARTICLEAlnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
Business Wire MAY 12, 2025 7:00 AM EDTAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today anno...READ ARTICLEAlnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
Business Wire MAY 5, 2025 10:00 AM EDTAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced ...READ ARTICLEAlnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
Business Wire MAY 1, 2025 8:00 AM EDT− Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28...READ ARTICLEAlnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Business Wire APR 28, 2025 8:00 AM EDT− Recommended Approval Based on the Pivotal HELIOS-B Phase 3 Study in which Vutrisiran Dem...READ ARTICLE